GO
Loading...

Pharmaceuticals

More

  • Mylan lowers price for Perrigo   Friday, 24 Apr 2015 | 10:37 AM ET
    Mylan lowers price for Perrigo

    CNBC's David Faber reports on pharmaceutical acquisitions making headlines including Mylan and Perrigo.

  • Epic battles brewing in pharma space   Friday, 24 Apr 2015 | 6:51 AM ET
    Epic battles brewing in pharma space

    CNBC's Meg Tirrell, and Jeremy Levin, Ovid Therapeutics CEO, survey the pharma landscape and discuss what's driving deal activity.

  • LONDON— Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales. Chief Executive Pascal Soriot said AstraZeneca was bolstering its oncology division, with 72 trials of cancer drugs underway. AstraZeneca shares fell 2.4 percent to 47.13 pounds...

  • That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to survey figures cited by analyst Robyn Karnauskas of Deutsche Bank.

  • April 23- U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira. Sales of AbbVie's all-oral hepatitis C treatment Viekira Pak, approved by U.S. regulators in December, came in at $231 million. AbbVie raised its full-year adjusted profit forecast to $4.10- $4.30 per share, from...

  • Drugmaker AbbVie profit rises on sales of Humira Thursday, 23 Apr 2015 | 7:55 AM ET

    April 23- U.S. drugmaker AbbVie Inc reported a 4 percent rise in quarterly profit, driven by strong sales of its arthritis drug, Humira. The company's profit rose to $1.02 billion, or 63 cents per share, in the first quarter ended March 31, from $980 million, or 61 cents per share, a year earlier. On an adjusted basis, the company earned 94 cents per share.

  • LLY CFO: Here's what's driving profits   Thursday, 23 Apr 2015 | 7:39 AM ET
    LLY CFO: Here's what's driving profits

    Derica Rice, Eli Lilly CFO breaks down the company's quarterly results, and talks about products in the pipeline as some drugs come off patent.

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • INDIANAPOLIS— Eli Lilly and Co.' s first-quarter earnings tumbled 27 percent as generic competition continued to eat away at sales for key products, but the drugmaker's performance topped expectations. Overall, Lilly earned $529.5 million, or 50 cents per share, in the quarter that ended March 31. Analysts forecast, on average, earnings of 76 cents per share,...

  • Lilly profit falls 27 percent, hurt by strong dollar Thursday, 23 Apr 2015 | 6:32 AM ET

    April 23- Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar. The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. Excluding items, the company earned 87 cents per share.

  • FRANKFURT, Germany— Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies. Novartis sold its animal health business to Lilly. It also bought cancer drugs from GSK and sold its non-flu vaccines business, while Novartis and GSK combined their...

  • Vitamin Shoppe rises as Carlson Capital boosts stake Wednesday, 22 Apr 2015 | 4:11 PM ET

    NEW YORK— Shares of nutritional supplement seller Vitamin Shoppe jumped Wednesday after the asset management firm Carlson Capital said it has boosted its stake in the company. Carlson Capital LP disclosed ownership of about 1.6 million shares of Vitamin Shoppe, giving it a 5.3 percent stake in the company. In a form filed with the Securities and Exchange...

  • The love-hate triangle in pharma   Wednesday, 22 Apr 2015 | 2:09 PM ET
    The love-hate triangle in pharma

    Corey Davis, Canaccord Genuity, discusses big deals in pharmaceutical including Teva's bid for Mylan.

  • Abbott posts profit beat   Wednesday, 22 Apr 2015 | 2:07 PM ET
    Abbott posts profit beat

    CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • COPENHAGEN, April 22- Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. Deputy Chief Executive Kaare Schultz told Reuters last...

  • Teva's turnaround CEO sets sights on $40 bln mega-deal Wednesday, 22 Apr 2015 | 9:06 AM ET

    TEL AVIV, April 22- Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries, is looking to pull off the ultimate transformation, with the biggest deal in Israel's corporate history. His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug...

  • FACTBOX-Teva Pharmaceutical's history of key acquisitions Wednesday, 22 Apr 2015 | 9:06 AM ET

    April 22- Teva Pharmaceutical Industries has offered to buy rival generic drugmaker Mylan for $40 billion in what would be the largest acquisition in Israel's history, equivalent to nearly 15 percent of GDP. *In March 2015 it said it would buy U.S. neurology drug company Auspex Pharmaceuticals for an equity value of $3.5 billion, a move to boost its portfolio of...

  • More M&A to come in biotech, pharma?   Wednesday, 22 Apr 2015 | 5:15 AM ET
    More M&A to come in biotech, pharma?

    David Seaburg, head of sales trading at Cowen and Company, explains why there's more M&A to come in the biotech and pharmaceutical sector.

  • LONDON, April 22- Swiss drugmaker Roche has "renewed confidence" that drugs targeting potentially brain-destroying plaque can fight Alzheimer's disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O'Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer's drugs, both of...